If a researcher introduces a drug that inhibits osteoclast activity in a 70-year-old patient with age-related bone loss, what effect dominates on bone density over the long term?

💡 Explanation

Osteoclasts break down bone; therefore, inhibiting them increases bone density because the balance shifts towards bone formation, causing reduced bone remodeling, rather than continuing bone breakdown. It's remodeling that's affected, rather than solely porosity because the imbalance disrupts the natural bone turnover cycle.

• Why does severe B12 deficiency primarily impair erythropoiesis (red blood cell production) in bone marrow, rather than equally affecting all rapidly dividing cells?
• Following sustained isometric contraction, which process risks tendon damage?
• Why does elevated protein concentration in Bowman's capsule fluid necessarily indicate glomerular filtration failure?
• Why does neuronal function decline during neurodegenerative diseases featuring protein aggregates like amyloid plaques or Lewy bodies?
• Why does reduced dietary mineral intake increase fracture risk in elderly individuals?
• What happens to antibody affinity in a patient with repeated influenza vaccinations over several years?